Nafcillin
Names | |
---|---|
Other names | Nafcillin sodium |
IUPAC name
| |
Clinical data | |
Drug class | Antibiotic (penicillin)[1] |
Main uses | Treat and prevent straphylococcal infections[1] |
Side effects | Pain at injection site, anaphylaxis, Clostridioides difficile infection[1] |
WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
Pregnancy category |
|
Routes of use | IM, IV |
External links | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a685019 |
Legal | |
Legal status |
|
Pharmacokinetics | |
Protein binding | 90% |
Metabolism | <30% liver |
Elimination half-life | 0.5 hours |
Excretion | Biliary and kidney |
Chemical and physical data | |
Formula | C21H22N2O5S |
Molar mass | 414.48 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Nafcillin, sold under the brand name Unipen among others, is an antibiotic used to treat and prevent straphylococcal infections.[1] This includes includes of the skin, respiratory tract, urine, and blood.[1] It is not effective against MRSA.[1] It is given by injection into a vein or muscle.[1]
Common side effects include pain and inflammation at the site of injection.[1] Other side effects may include anaphylaxis and Clostridioides difficile infection.[1] There is no evidence of harm with use in pregnancy, though such use has not been well studied.[2] It is a beta-lactam antibiotic of the penicillin type.[1] It is penicillinase resistant.[1]
Nafcillin was approved for medical use in the United States in 1965.[1] In the United States 10 doses of 2 grams costs about 90 USD as of 2021.[3] In 2012, out of 38 countries it was only available in one.[4]
Medical uses
Nafcillin is used to treat staphylococcal infections, except those caused by MRSA.[5]
Medical guidelines recommend either nafcillin or oxacillin as the first-line treatment for staphylococcal endocarditis in people without artificial heart valves.[6]
Dosage
It is given at a dose of 500 to 2,000 mg every 4 to 6 hours.[1]
Side effects
Serious life-threatening allergic reactions can occur.
Milder side-effects include:
- Hypokalemia[7]
- Nausea and vomiting
- Diarrhea, often due to suppression of normal gastrointestinal bacteria, which, on occasion, leads to a more serious super-infection with an organism like Clostridium difficile
- Abdominal pain
- Yeast infections (thrush) affecting the mouth and tongue or vagina
- Agranulocytosis, neutropenia
Interactions
There is evidence that nafcillin induces cytochrome P-450 enzymes, specifically CYP2C9. Several drugs with a narrow therapeutic window, such as warfarin and nifedipine, are metabolized by CYP2C9.[8]
Nafcillin contains salts added as stability media. These added salts could cause edema or fluid accumulation. It would be prudent to avoid this medication if there were a concern for a congestive heart failure or kidney disease.
References
- 1 2 3 4 5 6 7 8 9 10 11 12 13 "Nafcillin Monograph for Professionals". Drugs.com. Archived from the original on 24 January 2021. Retrieved 11 November 2021.
- ↑ "Nafcillin Use During Pregnancy". Drugs.com. Archived from the original on 4 December 2020. Retrieved 11 November 2021.
- ↑ "Nafcillin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 27 September 2017. Retrieved 11 November 2021.
- ↑ Pulcini, Céline; Bush, Karen; Craig, William A.; Frimodt-Møller, Niels; Grayson, M. Lindsay; Mouton, Johan W.; Turnidge, John; Harbarth, Stephan; Gyssens, Inge C. (15 January 2012). "Forgotten Antibiotics: An Inventory in Europe, the United States, Canada, and Australia". Clinical Infectious Diseases. 54 (2): 268–274. doi:10.1093/cid/cir838.
- ↑ Pham P, Bartlett JG (January 2, 2009). "Nafcillin". Point-of-Care Information Technology ABX Guide. Johns Hopkins University. Archived from the original on April 16, 2018. Retrieved August 5, 2021. Retrieved on July 10, 2009. Freely available with registration.
- ↑ Bonow RO, Carabello BA, Kanu C, et al. (August 2006). "ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons". Circulation. 114 (5): e84–231. doi:10.1161/CIRCULATIONAHA.106.176857. PMID 16880336.
- ↑ JA Mohr. (1979). Nafcillin-associated hypokalemia. JAMA
- ↑ Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, Lee TC (June 2003). "Evidence of an interaction between nifedipine and nafcillin in humans". Br J Clin Pharmacol. 55 (6): 588–90. doi:10.1046/j.1365-2125.2003.01789.x. PMC 1884262. PMID 12814453.
External links
Identifiers: |
---|